Table of Contents Table of Contents
Previous Page  21 / 220 Next Page
Information
Show Menu
Previous Page 21 / 220 Next Page
Page Background

19

Dear Members,

The Board of Directors (Board) presents the Annual Report of Atul Ltd together with the audited Financial Statements for the

year ended March 31, 2018.

01.

Financial results

(

cr

)

2017-18

2016-17

Sales

3,050

2,639

Revenue from operations

3,148

2,848

Other income

38

43

Total revenue

3,186

2,891

Profit before tax

397

400

Provision for tax

127

115

Profit for the year

270

285

Balance brought forward

1,397

1,145

Transfer from Comprehensive Income

3

3

Disposable surplus

1,670

1,433

Less:

   Dividend paid

30

30

  Dividend distribution tax (net)

3

6

Balance carried forward

1,637

1,397

02.

Performance

Sales increased by 16% from

`

2,639 cr to

`

3,050 cr

mainly due to higher volumes (12%) and prices (4%).

Sales in India increased by 24% from

`

1,239 cr

to

`

1,536 cr. Sales outside India increased by 8%

from

`

1,400 cr to

`

1,514 cr. The Earnings per share

decreased from

`

96.18 to

`

91.16. Cash flow from

operating activities before working capital changes

marginally decreased by 1% from

`

485 cr to

`

480 cr

and the net cash flow from operating activities

decreased by 12% from

`

370 cr to

`

325 cr.

Sales of Life Science Chemicals (LSC) Segment

increased by 27% from

`

807 cr to

`

1,026 cr, mainly

because of higher sales in Sub-segments Crop

Protection and Pharmaceuticals; its EBIT decreased

by 8% from

`

130 cr to

`

120 cr. Sales of Performance

and Other Chemicals (POC) Segment increased by

10% from

`

1,832 cr to

`

2,024 cr mainly because

of higher sales in Sub-segments Aromatics - II and

Polymers; its EBIT decreased by 3% from

`

290 cr to

`

281 cr. More details are given in the Management

Discussion and Analysis (MDA) Report.

The Company fully repaid entire borrowings of

`

155 cr despite payment towards capital expenditure

of

`

114 cr during the year.

Credit Analysis and Research Ltd (CARE) maintained

its credit rating at ‘AA+’ (double A plus) for

long-term borrowings of the Company. Its rating

for short-term borrowings and commercial paper

remained at ‘A1+’ (A1 plus), the highest possible

awarded by CARE.

03.

Dividend

The Board recommends payment of dividend of

`

 12 per share on 2,96,61,733 equity shares of

`

 10 each fully paid up. The dividend will entail

an outflow of

`

 42.91 cr {including dividend

distribution tax (net)} on the paid-up Equity share

capital of

`

 29.66 cr.

04.

Conservation of energy, technology

absorption, foreign exchange earnings

and outgo

Information required under Section 134 (3) (m)

of the Companies Act, 2013, read with Rule 8 (3) of

the Companies (Accounts) Rules, 2014, as amended

from time to time, forms a part of this Report which

is given at page number 24.

05.

Insurance

The Company has taken adequate insurance to cover

the risks to its employees, property (land and buildings),

plant, equipment, other assets and third parties.

06.

Risk Management

Risk Management is an integral part of business

practices of the Company. The framework of Risk

Management concentrates on formalising a system

to deal with the most relevant risks, building on

existing management practices, knowledge and

structures. With the help of a reputed international

consultancy firm, the Company has developed and

implemented a comprehensive Risk Management

System to ensure that risks to the continued

existence of the Company as a going concern and to

its growth are identified and remedied on a timely

basis. While defining and developing the formalised

Risk Management System, leading standards

and practices have been considered. The Risk

Management System is relevant to business reality,

pragmatic and simple and involves the following:

Directors’ Report